Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic
If necessity is the mother of invention, then medtech firms know what is expected of them in 2021 ̶ how they achieve it might be less straightforward
Executive Summary
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
You may also be interested in...
Harbinger Health CEO Stephen Hahn On Early Cancer Detection To ‘Move The Needle’ On Survival
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.
Now Available: Medtech Insight’s Top 100 Ranking Of Companies By Sales And 2021 Outlook
After a year like no other for the global medtech industry, 2021 will present a different set of market challenges for device and diagnostic companies.
Next Year’s Congress Likely To Reinforce ACA Preexisting Conditions, Attorneys Say
Industry attorneys predict that in the absence of the Supreme Court’s immediate response to arguments made in a key Affordable Care Act constitutionality case, that Congress will reaffirm the law.